Reuters logo
in 3 months
BRIEF-Loxo Oncology announces FDA clearance of investigational new drug application for next-generation trk inhibitor
May 30, 2017 / 10:55 AM / in 3 months

BRIEF-Loxo Oncology announces FDA clearance of investigational new drug application for next-generation trk inhibitor

May 30 (Reuters) - Loxo Oncology Inc

* Loxo Oncology announces fda clearance of investigational new drug (ind) application for next-generation trk inhibitor, loxo-195

* Loxo-195 will initially be studied in a multi-center phase 1/2 trial

* Loxo Oncology inc says primary objective of trial is to determine maximum tolerated dose or recommended dose for further study

* Trial will include a dose escalation phase and dose expansion phase

* Loxo Oncology - loxo-195 will be developed as sequential treatment, to follow larotrectinib/another trk inhibitor, to extend time for trk inhibition benefit Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below